<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00433121</url>
  </required_header>
  <id_info>
    <org_study_id>101</org_study_id>
    <nct_id>NCT00433121</nct_id>
  </id_info>
  <brief_title>Discontinuation of Antipsychotics and Antidepressants Among Patients With BPSD</brief_title>
  <official_title>Discontinuation of Antipsychotics and Antidepressants Among Patients With Dementia and BPSD Living in Nursing Homes - an Open Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sykehuset Innlandet HF</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Demensforbundet, Norway</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sykehuset Innlandet HF</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to discontinue antipsychotics and antidepressants, and to study its
      effect on Behavioural- and Psychological Symptoms in Dementia (BPSD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with dementia have cognitive deficits, but also hallucinations, delusions,
      agitation, aggression and apathy. These symptoms are called Behavioural- and Psychological
      Symptoms in Dementia (BPSD), and are difficult to treat. Antipsychotic and antidepressant
      medication is in use, despite its lack of clinical evidence.

      We will discontinue antipsychotics in one group of 12 patients and antidepressants in one
      group of 12 patients. Patients should have dementia of Alzheimer- or vascular origin. They
      should live in Nursing Homes and have no other psychiatric disease for which they receive
      psychotropic drug. They will be registered with 7 different questionnaires at baseline and
      after 3, 6, 12 and 24 weeks. The study period is 24 weeks. The questionnaires are filled in
      by the patients and the nurses at the nursing homes.

      This is an open labelled study with no control group. Based on the results of this study, we
      will design a RCT study with placebo-controlled group.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">August 2007</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in Neuropsychiatric Inventory</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in weight</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Cornell's Depression Scale</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in UPDRS subscale</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in &quot;Quality of Live - Alzheimer Disease&quot;</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Severe Impairment Battery</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Lawton's PADL</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxazepam given p.n.</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drop outs</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Dementia</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Discontinuation of neuroleptic or anti depressants</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Risperidone</intervention_name>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olanzapine</intervention_name>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Haloperidole</intervention_name>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Quetiapin</intervention_name>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Escitalopram</intervention_name>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Citalopram</intervention_name>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sertralin</intervention_name>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Vascular- or Alzheimer Dementia

          -  Nursing Homes resident for 3 months or more

          -  Given antipsychotics or antidepressants for 3 months or more

          -  Clinical Dementia rating 1, 2 or 3

        Exclusion Criteria:

          -  Dementia of other origin

          -  Psychiatric disease

          -  Life expectancy less than 3 months

          -  Acute infection last 10 days

          -  Unstable Diabetes Mellitus

          -  Terminal disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Knut Engedal, Ph D</last_name>
    <role>Study Chair</role>
    <affiliation>The Norwegian Centre for Dementia Research (NCDR), Norway</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sykehuset Innlandet HF - Sanderud</name>
      <address>
        <city>Ottestad</city>
        <state>Oppland</state>
        <zip>2312</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>August 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 1, 2007</study_first_submitted>
  <study_first_submitted_qc>February 8, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2007</study_first_posted>
  <last_update_submitted>August 23, 2007</last_update_submitted>
  <last_update_submitted_qc>August 23, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 24, 2007</last_update_posted>
  <keyword>Antidepressive Agents</keyword>
  <keyword>Neuroleptica</keyword>
  <keyword>Dementia</keyword>
  <keyword>Discontinuation study</keyword>
  <keyword>Behavioural- and Psychological Symptoms in Dementia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dementia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antidepressive Agents</mesh_term>
    <mesh_term>Citalopram</mesh_term>
    <mesh_term>Risperidone</mesh_term>
    <mesh_term>Antipsychotic Agents</mesh_term>
    <mesh_term>Olanzapine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

